Abstract: A solid pharmaceutical composition comprising a solid dispersion of a BCS Class II drug in a solid carrier/hydrophilic carrier; and a pH modifier. The solid carrier/hydrophilic carrier has a melting point of between about 40° C. to about 60° C. and an HLB value of between about 10 and about 18. The BCS Class II drug may be telmisartan.

Abstract: A compiler receives a graph describing a neural network and accesses data to describe a target computing device to implement the neural network. The compiler generates an intermediate representation from the graph and the data, and determines dependencies between operations identified in the intermediate representation. A set of barrier tasks are determined to be performed to control flow of the set of operations based on the dependencies, where the set of barrier tasks are to be performed using hardware barrier components on the target computing device. Indications of the barrier tasks are inserted into the intermediate representation. The compiler generates a binary executable from the intermediate representation to enable performance of the barrier tasks to control performance of the set of operations at the target computing device.

Abstract: A solid pharmaceutical composition comprising a solid dispersion of a BCS Class II drug in a solid carrier/hydrophilic carrier; and a pH modifier. The solid carrier/hydrophilic carrier has a melting point of between about 40° C. to about 60° C. and an HLB value of between about 10 and about 18. The BCS Class II drug may be telmisartan.